Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of CD64 Marker for Patients in Intensive Care Unit

NCT03617796 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT03617796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03617796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
Lead sponsor
Central Hospital, Nancy, France
Phase
Observational
Overall status
Unknown status
Start date
September 10, 2018
Completion date
December 31, 2018
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intensive care, systemic inflammatory response syndrome